Literature DB >> 2935336

CR1 deficiency in SLE: acquired or genetic?

G Uko, R L Dawkins, P Kay, F T Christiansen, P N Hollingsworth.   

Abstract

Erythrocytes from 30 patients suffering from systemic lupus erythematosus (SLE) were tested for CR1 activity by an immune adherence haemagglutination technique. Defective CR1 activity (CR1D) was found in 11 (37%) of the patients on initial testing. On repeat testings, however, CR1 activity often varied from time to time and was shown to be inversely related to serum anti-DNA binding and apparent complement activation in vivo. Two of the 19 patients with normal CR1 activity acquired CR1D during the study. One patient with previously defective CR1 attained normal activity in the course of the study. The increased occurrence of CR1D in patients with SLE is largely or wholly acquired rather than genetically determined.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2935336      PMCID: PMC1577435     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

2.  Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

3.  Two HLA-linked loci controlling the fourth component of human complement.

Authors:  G J O'Neill; S Y Yang; B Dupont
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

4.  A Millipore filter assay for antibodies to native DNA in sera of patients with systemic lupus erythematosus.

Authors:  B Ginsberg; H Keiser
Journal:  Arthritis Rheum       Date:  1973 Mar-Apr

5.  Immune adherence by the fourth component of complement.

Authors:  N R Cooper
Journal:  Science       Date:  1969-07-25       Impact factor: 47.728

6.  Stabilisation of C3 in EDTA-plasma at pH 6.0.

Authors:  E Ingham; G Gowland; K F Taylor
Journal:  Med Lab Sci       Date:  1985-01

7.  Distribution of HLA A, B and C antigens in an Australian population.

Authors:  B R Hawkins; J B Houliston; R L Dawkins
Journal:  Hum Genet       Date:  1979-11       Impact factor: 4.132

8.  Clinical applications of immunofixation: detection and quantitation of complement activation.

Authors:  J T Whicher; J Higginson; P G Riches; S Radford
Journal:  J Clin Pathol       Date:  1980-08       Impact factor: 3.411

9.  Inherited structural polymorphism of the fourth component of human complement.

Authors:  Z L Awdeh; C A Alper
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

10.  Genetic polymorphism in human glycine-rich beta-glycoprotein.

Authors:  C A Alper; T Boenisch; L Watson
Journal:  J Exp Med       Date:  1972-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Mechanisms of immune deposit formation in renal glomeruli.

Authors:  M H Wener; M Mannik
Journal:  Springer Semin Immunopathol       Date:  1986

2.  Erythrocyte complement receptor type 1 in non-SLE rheumatic diseases.

Authors:  J H Yen; H W Liu; S F Lin; T P Chen
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

3.  Serum C4 concentration in the monitoring of systemic lupus erythematosus: requirement for C4 allotyping.

Authors:  G Uko; F T Christiansen; R L Dawkins
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

4.  The rate of loss of CR1 from ageing erythrocytes in vivo in normal subjects and SLE patients: no correlation with structural or numerical polymorphisms.

Authors:  F Moldenhauer; M Botto; M J Walport
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

5.  Epistasis between the MHC and the RCA alpha block in primary Sjögren syndrome.

Authors:  S Lester; C McLure; J Williamson; P Bardy; M Rischmueller; R L Dawkins
Journal:  Ann Rheum Dis       Date:  2007-09-18       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.